(RAPT) RAPT Therapeutics - Ratings and Ratios

RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in immunology-based therapies. The company focuses on the discovery, development, and commercialization of oral small molecule therapies targeting unmet medical needs in oncology and inflammatory diseases. Its lead inflammation candidate, zelnecirnon (RPT193), is a CCR4 antagonist designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues, potentially addressing conditions like psoriasis and rheumatoid arthritis. The oncology pipeline is led by tivumecirnon (FLX475), an oral CCR4 antagonist currently in Phase 1/2 trials as both a monotherapy and in combination with pembrolizumab for advanced cancers, including solid tumors. Formerly known as FLX Bio, Inc., the company rebranded as RAPT Therapeutics in May 2019 and is headquartered in South San Francisco, California.

The stock is currently trading at $1.10, below its 20-day SMA of $1.17, signaling near-term bearish momentum. With an ATR of 0.11, volatility is relatively low, suggesting stable price movements. The fundamental outlook reflects a market cap of $165.01M and a P/S ratio of 411.22, indicating high valuation relative to revenue. The P/B ratio of 1.73 suggests moderate premium to book value.